October 13, 2016
Kite Pharma Appoints Chris Nowers as Head of Europe to Lead Commercial Operations and Advance the Company's CAR/TCR Therapy Portfolio in the Region
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161013005478/en/
"The addition of
A seasoned executive with 30 years of commercial leadership experience in pharmaceutical, biotech and diagnostics companies, Nowers brings a track record of successfully driving differentiated strategies for product commercialization across therapeutic areas in a competitive global landscape.
"Kite is a truly innovative company at the cusp of transforming the paradigm of cancer treatment, and I am honored to play a role in bringing what could potentially be life-changing therapies to patients around the world," said Nowers. "I look forward to working with such a dynamic and passionate team to advance our presence in
Prior to joining Kite, Nowers held senior commercial leadership positions at Bristol-Myers Squibb, including Head of Immuno-oncology and Hematology in
Kite Pharma's lead product candidate, KTE-C19, is an investigational therapy in which a patient's T cells are engineered to express a CAR to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. KTE-C19 has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.
About Kite Pharma
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to expand European operations, and obtain approval for and commercially launch KTE-C19 and additional product candidates internationally. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005478/en/
VP, Investor Relations
News Provided by Acquire Media